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Abstract
Background: Both video-assisted thoracic surgery (VATS) and thoracotomy are used for sleeve lobectomy for
patients with non-small cell lung cancer (NSCLC). This retrospective study aimed to assess the safety and efficacy of
VATS sleeve lobectomy for NSCLC patients.
Methods: Between May 2009 and May 2013, 51 sleeve lobectomies (10 by VATS and 41 by thoracotomy) were
performed for patients with NSCLC. Operative characteristics and postoperative course were compared between
two groups.
Results: Patient demographics were similar between the two groups. Thoracotomy patients had larger tumors
compared with VATS patients (p = 0.02). VATS patients had a longer operating time (p < 0.001) but a shorter length
of postoperative hospital stay (p = 0.009). The two groups did not differ in pathologic stage, histologic results, blood
loss, ICU stay, amount of chest drainage, duration of chest drainage, numbers and distributions of dissected lymph
nodes and the occurrence of complications. There were no perioperative deaths in the VATS group, whereas there
was one death (2.4 %) in the thoracotomy group. There were no conversions to thoracotomy in the VATS group.
The overall median survival between the two groups was similar (3.2 years VATS versus 3.2 years thoracotomy,
log-rank p = 0.58).
Conclusions: VATS sleeve lobectomy for the treatment of NSCLC is technically feasible and safe and is associated
with comparable complication rates and survival compared with thoracotomy approach, but it deserves further
investigation in large series.
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Background
Sleeve lobectomy, which is featured by not only the max-
imal resection of tumors but also the maximal reservation
of the normal lung tissues and lung functions, was consid-
ered as an alternative procedure to pneumonectomy for
patients with central lung cancer [1–4]. Although video-
assisted thoracic surgery (VATS) is regarded as a minim-
ally invasive procedure with good long-term survival
outcomes [5], many surgeons considered that sleeve resec-
tion was an absolute contraindication for VATS lobectomy
due to oncological concerns in obtaining a complete re-
section and technical complexity. Therefore, there are few
reports in the literature of VATS sleeve lobectomy for
lung cancer in recent years [6–14]. In addition, the pur-
ported benefits of VATS over thoracotomy in performing
sleeve lobectomy have only been reported in series using
only one surgical approach or in single case reports.
In this study, we conducted a retrospective study to
examine the safety and efficacy of the video-assisted
technique in the performance of sleeve lobectomies for
NSCLC patients and to compare the outcome from
these procedures with that from sleeve lobectomies per-
formed through a standard thoracotomy.
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We retrospectively reviewed the files of 10 patients who
underwent a sleeve lobectomy for non-small cell lung
cancer (NSCLC) by the VATS approach in the Depart-
ment of Thoracic Surgery at Beijing Chest Hospital,
Capital Medical University, between May 2009 and May
2013. The inclusion criteria for VATS sleeve lobectomy
include: endobronchial tumors and small tumors (tumor
size <5cm) with limited invasion of the bronchus; no evi-
dence of vessel invasion; no direct invasion to the sur-
rounding organs; no extensive pleural adhesion on the
CT scan;. and the ability to physiologically tolerate the
planned resection (Fig. 1). To better evaluate the safety
and effectiveness of the VATS approach, we reviewed
the files of 41 patients who underwent a sleeve lobec-
tomy for NSCLC by the open approach during the same
period at the same hospital (Fig. 2). Preoperative workup
included physical examination, chest roentgenography,
computed tomography of the chest and upper abdomen,
computed tomography or magnetic resonance imaging
of the brain, pulmonary function assessment, arterial
blood gases, bronchofiberscopy, electrocardiography,
and bone scintigraphy. Mediastinoscopy and positron
emission tomography were performed if necessary. The
study was approved by the ethics committee of Beijing
Chest Hospital, Capital Medical University, and all en-
rolled patients provided written informed consent.
Data collection
Patient demographics, preoperative investigations, tumor
characteristics, intraoperative details, and postoperative
course were recorded. Histologictyping occurred accord-
ing to The World Health Organization Histologic Typ-
ing of Lung Tumors. The postsurgical (pathologic)
stages of the patients were based on the seventh TNM
Classification of Malignant Tumors [15]. Postoperative
complications were defined as those occurring within 30
days of surgery. Hospital mortality included all deaths
during the first 30 days after operation, or during the
postoperative hospital stay.
Surgical technique
All operations were performed by two surgeons (Z.L. and
S.X.) with extensive experience in thoracoscopic and open
procedures from the same department. The decision to
employ either a VATS or thoracotomy approach was made
by the surgeons. All patients underwent standard
anesthesia care with the use of double-lumen endotracheal
tubes and perioperative fluid restriction. All patients were
performed in the lateral decubitus position.
The main difference in the conduct of the operation be-
tween VATS lobectomy and VATS sleeve lobectomy is the
need for a bronchial anastomosis. For VATS patients, we
choose the same incisions as the VATS lobectomy: a 10-
mm camera port placed in the eighth intercostal space
(ICS) at the midaxillary line; a 4-cm to 5-cm anterior util-
ity incision in the fourth or fifth ICS; a 10-mm incision in
the auscultatory triangle. Endoshears/Endokittners (U.S.
Surgical, Norwalk, CT, USA) were used for dissection.
Pulmonary vessels were resected as for standard lobec-
tomy using an EndoGIA vascular stapler (U.S. Surgical,
Norwalk, CT, USA).The bronchus was divided using scis-
sors. The bronchial stump was then assessed by frozen
Fig. 1 Chest computed tomography showing a tumor located
around bronchus of the right upper lobe
Fig. 2 Chest computed tomography showing a tumor located
around bronchus of the left upper lobe
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sectioning to be pathologically free of cancer. After patho-
logic examination, end-to-end bronchial anastomosis was
performed. In the first five cases, the bronchial anasto-
mosis was performed using interrupted sutures of 3-0
polyglactin 910 (Vicryl®, Ethicon Inc., Somerville, NJ,
USA). Interrupted sutures were first placed on the cartil-
aginous portions of the bronchial orifices, then on the
membranous portions. All sutures were held together in
the pleural cavity by agrasper inserted through the other
access port. After placing all sutures, knot tying was
started with a forceps-type tying instrument at the suture
placed at the deepest position. All sutures were tied, and
then the bronchoplasty was finally completed. In the
later five cases, continuous suture and three points
interrupted suture were performed using Vicryl® (Ethicon
Inc., Somerville, NJ, USA) 3-0 sutures for saving anasto-
mosis time (Fig. 3). The anastomosis was first initiated at
the junction of the cartilaginous and membranous walls
by using interrupted 3-0 polyglactin 910 (Vicryl®, Ethicon
Inc., Somerville, NJ, USA) suture. Absorbable 3-0 sutures,
with knots placed outside the bronchial lumen, are used
to decrease the possibility of stricture and granuloma
formation. Then followed by the continuous suturing
clockwise and counter clockwise for one third of the
circumference. Another two points of interrupted suturing
is followed when thecontinuous suturing is finished. The
final step is to complete the remaining one third of the
bronchus circumference using continuous suture. A
complete systemic mediastinal lymph node dissection was
performed after bronchial reconstruction. The resected
lobe was placed in an Endocatch bag (U.S. Surgical,
Norwalk, CT, USA). A sealing test was performed to con-
firm that there was no leakage after completion of the
anastomosis. Two 28F chest tubes were placed and the in-
cisions were closed. Postoperative bronchoscopy was per-
formed to clear blood and secretions, and to confirm that
there was no stenosis after the operation.
For thoracotomy patients, sleeve lobectomy was per-
formed though a traditional posterolateral thoracotomy in-
cision at the fifth intercostal space. The surgical technique
used in the thoracotomy approach was similar to that of
VATS, except for the method of the bronchial anastomosis,
which was performed using several interrupted3-0 absorb-
able sutures in all thoracotomy patients.
Postoperative management
All patients were extubated in the operating or recovery
room and were kept in the intensive care unit (ICU)
until stable. All patients had intraoperative and postop-
erative antibiotic prophylaxis. Patient controlled intra-
venous analgesia (PCIA) for postoperative pain relief
was offered to all patients regardless of the planned op-
erative approach. The chest tube was removed if the
drainage volume was less than 200 ml per day and no
air leakage was observed. Fiberoptic bronchoscopy was
routinely performed before discharge.
Statistical analysis
The data are presented as frequency and percentage for
categoric variables and as mean ± standard deviations for
continuous variables. The Wilcoxon rank test were used
to compare continuous variables and the χ2 or Fisher
exact tests were used for categorical variables. Survival
was recorded from the day of surgery until death or the
last follow-up contact. Survival analysis was estimated
by the Kaplan-Meier method and compared by the log-
rank test. A p value less than 0.05 was considered to be
significant. The statistical software SPSS 16.0 (SPSS Inc.,
Chicago, IL, USA) was used for all analyses.
Results
During the study period, 51 patients, 10 VATS (20 %)
and 41 thoracotomy (80 %), underwent sleeve lobectomy
for NSCLC. Demographics, baseline characteristics, and
comorbidities of the VATS and thoracotomy patients are
shown in Table 1. There were more male patients in
both groups. Comorbidities and preoperative pulmonary
function values were comparable between two groups.
Fig. 3 Bronchial anastomosis was performed using continuous
suture and three points interrupted suture
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No patient had a history of neoadjuvant treatments or
thoracotomy in both two groups.
Tumor characteristics and operative details are listed
in Table 2. Thoracotomy patients had larger tumors
compared with VATS patients (p = 0.02). Right upper
sleeve lobectomy was the most common procedure in
both two groups. No statistically significant difference
was found in either the distribution of pathologic stages
or the histologic results between two groups. The most
common histologic type in both two groups was squa-
mous cell carcinoma. The mean number of lymph nodes
resected and the distribution of resected nodal status
were similar between two groups. The average operating
time was significantly longer in the VATS group than in
the thoracotomy group (226 ± 37 min versus166 ± 40
min, p < 0.001). There were no conversions to thoracot-
omy in the VATS group. As shown in Table 2, no statis-
tically significant difference was found between two
groups in terms of the estimated blood loss, amount of
chest drainage, duration of chest drainage, and the
length of intensive care unit(ICU) stay. However, the
mean length of postoperative hospital stay was signifi-
cantly shorter in the VATS group than in the thoracot-
omy group (11.6 ± 2.8days vs. 16.1 ± 4.9 days, p = 0.007).
The various postoperative complications are listed in
Table 3. Onepatient (10.0 %) of the VATS group and 10
(24.4 %) of the thoracotomy group experienced postop-
erative complications (p = 0.62). In addition, one patient
in the thoracotomy group experienced bronchopleural
fistula on the 46th postoperative day. The patient was
treated with bronchoscopic interventions using glues
and discharged two weeks later. There were no peri-
operative deaths in the VATS group, whereas there was
one death (2.4 %) in the thoracotomy group although
this difference was not statistically significant. This pa-
tient died of pulmonary embolus 15 days after operation.
All patients completed follow-up and all patents (n = 51)
were included in the survival analysis. Median follow-up
was 34 months in both groups. The overall median
survival between the two groups was similar (log-rank,
Table 1 Patient characteristics
Variable Thoracotomy (n = 41) VATS (n = 10) p Value
Gender 35M/6F 9M/1F 1.00
Age (y) 62.5 ± 7.2 60.5 ± 16.9 0.72
Tobacco use 16 (39.0 %) 3 (30.0 %) 0.61
Comorbiditiesa
Hypertension 10 (24.4 %) 4 (40.0 %) 0.33
Diabetes mellitus 3 (7.3 %) 1 (10.0 %) 0.78
Coronary artery disease 8 (19.5 %) 2 (20.0 %) 0.97
COPD 8 (19.5 %) 2 (20.0 %) 0.97
Pulmonary function
FVC (L) 3.1 ± 0.6 3.2 ± 0.3 0.38
FEV1 (L) 2.2 ± 0.5 2.3 ± 0.2 0.11
FEV1/FVC % 70.3 ± 8.9 73.5 ± 4.8 0.14
aSome patients had one or more comorbidities
COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory
volume in 1 second; FVC = forced vital capacity
Table 2 Tumor characteristics and operative details
Variable Thoracotomy VATS p Value
Tumor size (cm) 3.6 ± 1.2 2.7 ± 0.9 0.02
Total lymph nodes 22.0 ± 8.3 25.7 ± 6.5 0.20
Total lymph node stations 6.8 ± 1.4 6.4 ± 0.7 0.43
Histologic Type 0.55
Squamous cell carcinoma 33 (80.5 %) 8 (80.0 %)
Adenocarcinoma 7 (17.1 %) 1 (10.0 %)
Othera 1 (2.4 %) 1 (10.0 %)
Pathologic stage 0.36
I 18 (43.9 %) 6 (60.0 %)
II 10 (24.4 %) 2 (20.0 %)
IIIa 13 (31.7 %) 2 (20.0 %)
Type of lung resection 0.31
Right side 30 (73.2 %) 7 (70.0 %)
Left side 11 (26.8 %) 3 (30.0 %)
Upper lobe 24 (58.5 %) 6 (60.0 %)
Middle lobe 1 (2.4 %) 1 (10.0 %)
Lower lobe 8 (19.5 %) 3 (30.0 %)
Upper and middle lobe 2 (4.9 %) 0
Lower and middle lobe 6 (14.6 %) 0
Operating time (min) 166 ± 40 226 ± 37 <0.001
Estimated blood loss (mL) 318 ± 198 406 ± 200 0.22
Intensive care unit (hours) 20.3 ± 1.7 19.1 ± 1.6 0.06
Chest tube drainage (mL) 2229 ± 1508 2247 ± 990 0.97
Chest tube duration (days) 8.6 ± 5.1 7.5 ± 1.7 0.50
Postoperative hospital stay (days) 16.1 ± 4.9 11.6 ± 2.8 0.009
aOther results included carcinoid, or neuroendocrine carcinoma
Table 3 Complications
Complication Thoracotomy VATS p Value
Prolonged air leak 2 0




Bronchopleral fistulaa 0 0
Pulmonary embolus 1 0
Total 10 (24.4 %) 1 (10.0 %) 0.57
aOne patient in the thoracotomy group experienced bronchopleural fistula on
the 46th postoperative day
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p = 0.58) (Fig. 4). For the VATS group, the median sur-
vival estimate was 3.2 years; the overall 1-, 2-, 3-, and
4-years survival rates were 100 %, 89 %, 73 %, and 40 %
respectively. For the thoracotomy group, the median
survival estimate was 3.2 years; the overall 1-, 2-, 3-,
and 4-years survival rates were 100 %, 84 %, 63 %, and
56 % respectively.
Discussion
Since the technique of VATS lobectomy was first de-
scribed in the early 1990s, a number of studies have
demonstrated its safety and advantages [16–18]. During
the following years, VATS lobectomy gained widespread
acceptance in the treatment of lung cancer, and eventu-
ally written into the guideline for the diagnosis and
treatment of lung cancer [19]. However, the application
of VATS sleeve lobectomy has been somewhat limited
due to oncological concerns in obtaining a complete re-
section and technical complexity. Since the first case of
VATS sleeve lobectomy was reported in 2002 [20], more
and more studies had described the application of VATS
sleeve lobectomy include uniportal VATS bronchial
sleeve lobectomy [9–11] and even thoracoscopic double
sleeve lobectomy [12, 13]. In this study we reviewed our
experience with open and thoracoscopic sleeve lobec-
tomy in order to prove the safety and efficacy of the
VATS procedure.
The results of the current study demonstrate that
VATS sleeve lobectomy can be safely performed with a
favorable postoperative outcome compared with the
thoracotomy approach. The VATS approach provides an
obvious advantage of the thoracotomy technique in the
aspect of postoperative hospital stay. However, the VATS
group had a longer operating time than the thoracotomy
group. It is because VATS patients require a significant
longer anastomosis time than thoracotomy patients. The
average anastomosis time in the VATS group, which re-
corded using a prospective database, was 55 ± 18 min.
Like all other procedures, VATS sleeve lobectomy also
has a learning curve for both the surgeon and the assist-
ant. It is believed that the perioperative outcomes such
as operating time and anastomosis time would be re-
duced after the initial learning period.
Due to oncological concerns of complete resection
and technical complexity, only small tumors with limited
invasion of the main bronchus without major invasion
of the pulmonary artery were selected for VATS sleeve
lobectomy by careful preoperative computed tomog-
raphy of the chest and bronchofiberscopy. In the present
study, there were no conversions to thoracotomy in the
VATS group. The same results have been reported in
several previous studies [6, 7, 21, 22]. Interference by
lymph nodes and bleeding are the most important
causes of conversion to thoracotomy in video-assisted
thoracoscopic surgery. Patient selection bias may have
played a role in the favorable results. Indications for
VATS sleeve lobectomy as well as thresholds for conver-
sions vary among surgeons, and these factors change
over time as the surgeon gains more experience with the
procedure.
The major complications after sleeve lobectomy in-
clude pneumonia, secondary atelectasis, and bronchial
Fig. 4 Kaplan-Meier curve for overall survival by VATS (black line) and thoracotomy (gray line)
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complications [23, 24]. However, bronchial anastomotic
complications including bronchovascular and bronchopl-
eral fistula, anastomotic stricture, and anastomotic dehis-
cence are probably the most serious complications
associated with sleeve lobectomy. In our present study,
only one patient in the thoracotomy group experienced
bronchopleural fistula on the 46th postoperative day,
whereas there was no bronchial anastomotic complications
in the VATS group. The postoperative complication rates
after VATS sleeve lobectomy vary in different reports.
Mahtabifard et al. reported that four of 13 (31 %) patients
undergoing VATS sleeve lobectomy experienced postoper-
ative complications, including atrial fibrillation, anasto-
motic stricture, reintubation, and bronchial tear requiring
repair [7]. Wang et al. have described the successful use of
VATS sleeve lobectomy with only one patient in their co-
hort of 15 (6.7 %) experiencing minor complications [22].
Similarly, Agasthian reported that only one patient (4.8 %)
developed bronchopleural fistula in a cohort of 21 patients
who underwent VATS bronchoplasy [8]. Conversely, some
studies have indicated that VATS sleeve lobectomy can be
performed safely without major postoperative complica-
tions [6, 21]. Such variability probably depends on the
characteristics of studied populations, the surgeon’s skill-
level, and postoperative management. In our study, al-
though there was only one patient (10 %) experienced
atrial fibrillation and no death occurred in the VATS group,
no significant differences were found between the two
groups in terms of morbidity and mortality. Also, the inci-
dence of postoperative complications and mortality rate in
our series were in agreement and compare favorably with
previous reports [8, 22]. Patient selection bias and low
statistical power may account for this observation.
Our findings support those of previously published
reports that have demonstrated that complete mediastinal
lymph node dissection through a VATS approach is feas-
ible and that results are equivalent to those of a thoracot-
omy approach. Sugi et al. found no difference between the
numbers of lymph nodes dissected among VATS versus
open group during lobectomy [25]. Similarly, Watanabe
et al. conducted a retrospective review of 770 patients
with cN0-pN2 NSCLC (VATS = 450, open = 320) and
found no difference in terms of the total number of lymph
nodes, number of lymph node stations, number of medi-
astinal nodes and mediastinal stations between VATS and
open lobectomy [26]. Data from the recent ACSOG
Z0030 trial also showed no difference between VATS and
thoracotomy for node dissection [27].
The best measure of any cancer treatment is survival.
To date, no studies have reported the long-term out-
comes after VATS sleeve lobectomy. In our study, al-
though we could not compare the 5-year survival rate
after sleeve lobectomy between VATS and thoracotomy
due to the short-term follow up, the median survival
between the two groups was similar and no significant dif-
ferences were found between the two groups in 1-, 2-, 3-,
and 4-years survival rates. It appears that a VATS approach
does not compromise the survival for lung cancer patients.
A full-thickness interrupted suture is the most popular
technique for anastomosis and is widely employed.
Mckenna et al. performed interrupted suturing with 3-0
Vicryl sutures [7]. Of the 13 patients reported, two (15.4 %)
had bronchial anastomotic complications including anasto-
motic stricture and bronchial tear requiring repair. How-
ever, the end-to-end anastomosis could also be performed
by complete continuous suture. The safety of the continu-
ous suturing technique has been reported by Kutlu et al. in
a series of 100 patients using 3-0 propylene sutures
with 2 % bronchopleural fistula, 1 % bronchovascular fis-
tula, and 5 % late stenosis [28]. The other technique in-
volves closing the membranous portion of the bronchus
with a simple continuous suture, and the closure of the
cartilaginous portion with simple interrupted sutures [29].
Although interrupted anastomosis is relatively reliable, the
sutures were sometimes placed with the knots in the bron-
chial lumen, which usually resulted in postoperative spu-
tum retention, irritable cough, and anastomotic stricture.
In contrast, continuous anastomosis avoided entanglement
of the sutures and prevented against too much tightening
of the anastomotic sites. However, the limitation of the
continuous anastomosis is that one-site interruption of the
suture would lead to anastomosis failure. Continuous anas-
tomosis combined with interrupted consolidation used in
our study avoided the presence of absorbable suture
placing in the bronchial lumen, therefore decreasing post-
operative sputum retention and irritable cough. It also de-
creased the anastomosis time. In addition, some authors
believe that bronchial anastomotic complications can be
prevented by precise dissection, preservation of bronchial
blood supply, and interposition of pedicled tissue between
the bronchial and vascular structures [30].
Some limitations in the present study need to be ac-
knowledged. First, the main limitation of this study is the
non-randomized and retrospective nature. Unknown con-
founding variables and imbalance between patient charac-
teristics, such as tumor size, could bias the results.
Second, VATS sleeve lobectomy was performed for only
10 patients during our study period due to its technical
complexity. The small sample size can have effects on the
outcome and worth of the study. Third, although the
current data have shown that VATS sleeve lobectomy can
produce similar outcomes with open surgery, it must be
borne in mind that the selection bias for VATS sleeve lob-
ectomy may predispose them to an improve outcome.
Conclusions
Despite a small sample size, we can preliminarily con-
clude that VATS sleeve lobectomy is technically feasible
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and safe for selected patients in specialized centers.
VATS sleeve lobectomy can be performed with compar-
able complication rates and survival compared with the
thoracotomy approach. However, VATS sleeve lobec-
tomy is associated with a significantly decreased length
of hospital stay. The non-randomized retrospective de-
sign might make multiple factors have biased the results.
Therefore, further randomized controlled studies with
large series may be necessary.
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